Medical Condition News

RSS

A personalized elimination diet changed the gut microbiome in people with migraine

In a 12-week randomized, sham-controlled trial of 98 adults with migraine, eliminating IgG-positive foods altered gut microbial composition and produced a greater reduction in serum zonulin than a sham elimination diet. The microbial changes were associated with previously reported reductions in CGRP and IL-6 and improvements in migraine and sleep, although the authors emphasized that these mechanistic links remain exploratory.

31 Aug 2026

Exercise intervention associated with reduced atrial fibrillation burden

An exercise program combining short-term supervision with long-term home-based exercise was associated with reduced atrial fibrillation burden and other meaningful benefits, according to results presented in a Hot Line session today at ESC Congress 2026.

31 Aug 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

SHASTA trials show substantial triglyceride reductions with plozasiran

Plozasiran treatment resulted in substantial reductions in triglyceride levels in patients with severe hypertriglyceridemia after one year, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Blood pressure intervention lowers dementia risk in community-based trial

In a community-based trial in rural China, an intensive blood-pressure lowering intervention reduced the incidence of dementia compared with usual care, according to results from the China Rural Hypertension Control Program presented in a Hot Line session today at ESC Congress 2026.

30 Aug 2026

Catheter ablation reduces AF recurrence but not quality of life

Catheter ablation for atrial fibrillation (AF) did not significantly improve AF-related quality of life compared with a sham procedure, despite reducing AF recurrence.

30 Aug 2026

TAVI-first strategy proves noninferior to PCI-first approach in new trial

A TAVI-first strategy was noninferior to a PCI-first strategy after one years' follow-up, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

30 Aug 2026

Starting statins early after diabetes diagnosis linked to lower dementia risk

Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

30 Aug 2026

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

People with diabetes may have another reason to protect their cardiovascular health

Better cardiovascular health, measured using Life’s Essential 8, was associated with a lower risk of mild cognitive impairment among people with diabetes after accounting for genetic susceptibility. Associations with dementia varied by genetic risk, while higher LE8 scores were also linked to greater gray matter volume and lower white matter hyperintensity volume.

30 Aug 2026

Remote exercise-based cardiac rehabilitation can be an additional option for heart patients

Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions as center-based programs only, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Rapid pathway for diagnosing heart attacks does not improve emergency discharge rates

A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED.

29 Aug 2026

Functional angiography outperforms conventional imaging in AIR-STEMI trial

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.

29 Aug 2026

Digital registry strategy doubles heart failure treatment uptake

A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than doubled implementation of an effective type of heart failure treatment.

29 Aug 2026

FDA approves daraxonrasib for patients with metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.

29 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026